• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Abbvie to Gilead 1 out of 10 on national insurance plans

Quote

Anonymous

Guest
So - someone verify the breakdown -

Abbvie
ESI (not all plans and employer groups will follow)
VA (for every 5 VP you get 2 or 3 Harvoni)
Magellan

Gilead
Kaiser
United Healthcare
Aetna
Healthnet
Anthem
CVS Caremark
There's more, but not sure what I'm missing here...

How screwed are we in terms of access? Based on the insurance plans favoring Gilead - do we expect a 5-10% market share?

Who is screwed the most? West Coast? East coast ? Mid West? Southern states? How is Abbvie going to base quotas fairly and accurately based on your areas managed care situation? This cannot be good for anyone...or is it? Please sound in.... (I'm not a troll by the way .... Just want someone to break it down for me so my manager doesn't try to manipulate the facts and I know what to expect when bonuses are given...if at all).
 








Anonymous said:
So - someone verify the breakdown -

Abbvie
ESI (not all plans and employer groups will follow)
VA (for every 5 VP you get 2 or 3 Harvoni)
Magellan

Gilead
Kaiser
United Healthcare
Aetna
Healthnet
Anthem
CVS Caremark
There's more, but not sure what I'm missing here...

How screwed are we in terms of access? Based on the insurance plans favoring Gilead - do we expect a 5-10% market share?

Who is screwed the most? West Coast? East coast ? Mid West? Southern states? How is Abbvie going to base quotas fairly and accurately based on your areas managed care situation? This cannot be good for anyone...or is it? Please sound in.... (I'm not a troll by the way .... Just want someone to break it down for me so my manager doesn't try to manipulate the facts and I know what to expect when bonuses are given...if at all).
Click to expand...

I believe we got Geisinger and Gilead got UPMC.
 








Anonymous said:
Bonuses are earned, not given. This ain't PC.
Click to expand...

No shit Sherlock! Thanks for clarifying that for me. I'm sure you're one of those "ride your ass" managers who all provider offices hate!

In specialty sales, due to the cost of the medications, preferred and parity managed care situations are crucial in having a big part of your success. PC meds are chump change compared to what we are dealing with - not to mention the "hassle" factor of our regimen that also is much more complicated than most PC meds.

But thank you again for being the "Ahole" I'm sure that you are!
 




They won harvard pilgrim and cigna. BUT, let's not give up yet. Your manager and the tree stooges have no incentive to tell us anything negative. They want us working our asses off for them. Just remember, stay classy and maintain relationships. We will need them in the future for either Gen 2 or a different company. So, don't whore yourself for VPak. I hear gilead is starting a new hiv team. Might be worth looking there before you have the "severance" discussion.

But, for now, just SELL so we can stay afloat. We are fine until October. That's the decision day for Vpak (go or no go).
 








Anonymous said:
So - someone verify the breakdown -

Abbvie
ESI (not all plans and employer groups will follow)
VA (for every 5 VP you get 2 or 3 Harvoni)
Magellan

Gilead
Kaiser
United Healthcare
Aetna
Healthnet
Anthem
CVS Caremark
There's more, but not sure what I'm missing here...

How screwed are we in terms of access? Based on the insurance plans favoring Gilead - do we expect a 5-10% market share?

Who is screwed the most? West Coast? East coast ? Mid West? Southern states? How is Abbvie going to base quotas fairly and accurately based on your areas managed care situation? This cannot be good for anyone...or is it? Please sound in.... (I'm not a troll by the way .... Just want someone to break it down for me so my manager doesn't try to manipulate the facts and I know what to expect when bonuses are given...if at all).
Click to expand...

specialty pharmacy rep ---one of the big three, harvoni/solvadi out selling you 50 to one numbers do not lie
 




Also VA business seems to be going to Gilead. We are apparently both on CMOP formulary. Drug interactions, Adhearence among the issues why doctors are no using is there. Gilead gave a deep discount according to pharmacist.
 




Anonymous said:
Also VA business seems to be going to Gilead. We are apparently both on CMOP formulary. Drug interactions, Adhearence among the issues why doctors are no using is there. Gilead gave a deep discount according to pharmacist.
Click to expand...

Time Out!! No more negative posts dicky heads!! Go Sell and don't worry about a sh*tty regimen! Just spend more on lunches!!! Work those Saturday mornings!!!
 
















Anonymous said:
So - someone verify the breakdown -

Abbvie
ESI (not all plans and employer groups will follow)
VA (for every 5 VP you get 2 or 3 Harvoni)
Magellan

Gilead
Kaiser
United Healthcare
Aetna
Healthnet
Anthem
CVS Caremark
There's more, but not sure what I'm missing here...

How screwed are we in terms of access? Based on the insurance plans favoring Gilead - do we expect a 5-10% market share?

Who is screwed the most? West Coast? East coast ? Mid West? Southern states? How is Abbvie going to base quotas fairly and accurately based on your areas managed care situation? This cannot be good for anyone...or is it? Please sound in.... (I'm not a troll by the way .... Just want someone to break it down for me so my manager doesn't try to manipulate the facts and I know what to expect when bonuses are given...if at all).
Click to expand...

OMG, this is worse than the pill ratio that is taking us down. Do the math people; Oh Crappie it's all about the math! Why can't you bean counters at the top add it up?
 




Anonymous said:
OMG, this is worse than the pill ratio that is taking us down. Do the math people; Oh Crappie it's all about the math! Why can't you bean counters at the top add it up?
Click to expand...

They are looking to the future with 2nd gen. Most of us will have been disposed of via layoffs by the time it hits the market. Timing is everything. Once Harvoni was approved VPak was a bust. Ask anyone at HQ.
 




Anonymous said:
They are looking to the future with 2nd gen. Most of us will have been disposed of via layoffs by the time it hits the market. Timing is everything. Once Harvoni was approved VPak was a bust. Ask anyone at HQ.
Click to expand...

VPak development shoułd have been shelved in favor of fast tràcking second generation once Gilead filed for Harvoni approval. VPak was outdated as soon as we saw the Ion data.
 
















Here is one more to make your head explode. ABBV credit rating A-, pay out vendors and depts on time. And don't be so leveraged. Secondly read some analyst reports. ABBV is Shabvie! Marginal performance expected. Wah Wah Waaaaaaaaaah! That why it time to bail!
 




Top Bottom
Back
Quote